[go: up one dir, main page]

PE20130198A1 - Composiciones solidas - Google Patents

Composiciones solidas

Info

Publication number
PE20130198A1
PE20130198A1 PE2012001536A PE2012001536A PE20130198A1 PE 20130198 A1 PE20130198 A1 PE 20130198A1 PE 2012001536 A PE2012001536 A PE 2012001536A PE 2012001536 A PE2012001536 A PE 2012001536A PE 20130198 A1 PE20130198 A1 PE 20130198A1
Authority
PE
Peru
Prior art keywords
carboxamide
solid compositions
hcv
diazaciclopentadecin
cyclopropylsulphonil
Prior art date
Application number
PE2012001536A
Other languages
English (en)
Inventor
Bernd Liepold
Karin Rosenblatt
Peter Holig
Rajeev Gokhale
Leena Prasad
Jonathan Miller
Eric A Schmitt
John B Morris
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of PE20130198A1 publication Critical patent/PE20130198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA QUE CONTIENE: A) UN INHIBIDOR DEL VIRUS DE LA HEPATITIS C (HCV) TAL COMO (2R,6S,13aS,14aR,16aS,Z)-N-(CICLOPROPILSULFONIL)-6-(5-METILPIRAZIN-2-CARBOXAMIDO)-5,16-DIOXO-2-(FENANTRIDIN-6-ILOXI)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-HEXADECAHIDROCICLOPROPA[e]PIRROLO[1,2-a][1,4]DIAZACICLOPENTADECIN-14a-CARBOXAMIDA; B) UN POLIMERO HIDROFILICO TAL COMO UN HOMOPOLIMERO O COPOLIMERO DE N-VINIL PIRROLIDONA, COPOVIDONA, ENTRE OTROS; C) UN AGENTE TENSIOACTIVO TAL COMO LAURATO DE PROPILENGLICOL, POLISORBATO 80, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE INFECCIONES DEL HCV
PE2012001536A 2010-03-10 2011-03-08 Composiciones solidas PE20130198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33996410P 2010-03-10 2010-03-10

Publications (1)

Publication Number Publication Date
PE20130198A1 true PE20130198A1 (es) 2013-03-24

Family

ID=44564075

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001536A PE20130198A1 (es) 2010-03-10 2011-03-08 Composiciones solidas

Country Status (28)

Country Link
US (1) US20110312973A1 (es)
EP (1) EP2544689B1 (es)
JP (2) JP5717768B2 (es)
KR (1) KR101579079B1 (es)
CN (2) CN103118681B (es)
AR (1) AR081736A1 (es)
AU (1) AU2011224558B2 (es)
BR (1) BR112012022774A2 (es)
CA (1) CA2792601C (es)
CL (1) CL2012002500A1 (es)
CO (1) CO6640208A2 (es)
DO (1) DOP2012000245A (es)
EA (1) EA021570B1 (es)
EC (1) ECSP12012148A (es)
ES (1) ES2613608T3 (es)
GT (1) GT201200257A (es)
IL (1) IL221833A (es)
MX (1) MX2012010478A (es)
MY (1) MY156888A (es)
NZ (1) NZ602288A (es)
PE (1) PE20130198A1 (es)
PH (1) PH12012501784A1 (es)
SG (1) SG183985A1 (es)
TW (1) TWI490218B (es)
UA (1) UA104517C2 (es)
UY (1) UY33265A (es)
WO (1) WO2011112558A2 (es)
ZA (1) ZA201207093B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678148B2 (ja) 1983-12-27 1994-10-05 北海製罐株式会社 缶胴ブランクの選別装置
DK2593463T3 (da) * 2010-07-12 2020-08-10 Salix Pharmaceuticals Inc Formuleringer af rifaximin og anvendelser deraf
MX2013007698A (es) * 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
US9044480B1 (en) 2011-03-03 2015-06-02 Abbvie Inc. Compositions and methods for treating HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP2014530195A (ja) * 2011-09-16 2014-11-17 アッヴィ・インコーポレイテッド Ｈｃｖを治療するための方法
ES2572330B1 (es) * 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa (aad) para su uso en el tratamiento del vhc
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
CN104023726A (zh) * 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
AU2013201758B2 (en) * 2011-10-21 2014-11-27 Abbvie Ireland Unlimited Company Methods for treating HCV
AU2015100275B4 (en) * 2011-10-21 2015-06-11 Abbvie Ireland Unlimited Company Methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
CA2876496A1 (en) * 2012-06-27 2014-01-03 Abbvie Inc. Methods for treating hcv
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
CA2878689A1 (en) 2012-07-12 2014-01-16 Abbvie Inc. Crystalline forms of an hcv inhibitor
IN2015DN02875A (es) 2012-09-11 2015-09-11 Medivation Prostate Therapeutics Inc
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
EA029088B1 (ru) 2013-03-15 2018-02-28 Джилид Сайэнс, Инк. Макроциклические и бициклические ингибиторы вируса гепатита c
EP3016651A1 (en) 2013-07-02 2016-05-11 AbbVie Inc. Methods for treating hcv
PL3043803T3 (pl) 2013-09-11 2022-11-07 Emory University Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
WO2015084953A1 (en) * 2013-12-04 2015-06-11 Abbvie Inc. Crystal forms
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3099295A1 (en) 2014-01-28 2016-12-07 Abbvie Inc. Dose adjustment in combination therapy of hepatitis c
BR112016024421A2 (pt) * 2014-06-18 2017-08-15 Chugai Pharmaceutical Co Ltd composição farmacêutica, cápsula e uso da composição farmacêutica
US20160074462A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Method of Treating HCV
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
EP3381451B1 (en) * 2015-08-28 2025-08-20 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
KR102494049B1 (ko) 2016-09-30 2023-01-31 샐릭스 파마슈티컬스 인코포레이티드 리팍시민의 고체 분산물 형태
KR102419759B1 (ko) * 2017-03-15 2022-07-12 세레신 인코포레이티드 고 약물 부하량의 중쇄 트리글리세라이드를 갖는 약학 조성물 및 이와 관련된 방법
US10004719B1 (en) 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
HUE069633T2 (hu) 2018-11-30 2025-04-28 Chemocentryx Inc Kapszulás készítmények
JP2022039996A (ja) * 2020-08-26 2022-03-10 アムジエン・インコーポレーテツド Ｍｃｌ－１阻害剤処方物
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2023154171A1 (en) * 2022-02-14 2023-08-17 Purdue Research Foundation Polymer salts for improved drug delivery from amorphous solid dispersions
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
AU2004231538A1 (en) * 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CN1274300C (zh) * 2003-12-11 2006-09-13 中国科学院生物物理研究所 用于改善姜黄素溶出度和生物利用度的药物组合物及其制备方法
CA2578356C (en) * 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
TW200716631A (en) * 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
EP1912996B1 (en) * 2005-07-29 2012-06-20 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
AR061629A1 (es) * 2006-06-26 2008-09-10 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
MX2010006659A (es) * 2007-12-21 2010-07-05 Hoffmann La Roche Proceso para la preparacion de un macrociclo.
CA2720729A1 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
EP2323631A1 (en) * 2008-08-07 2011-05-25 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US20110229438A1 (en) * 2008-10-09 2011-09-22 Anadys Pharmaceuticals, Inc. Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US8476225B2 (en) * 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
EP2544689A4 (en) 2014-04-02
WO2011112558A3 (en) 2012-01-05
CA2792601C (en) 2015-09-29
PH12012501784A1 (en) 2022-10-05
BR112012022774A2 (pt) 2017-09-12
JP2013522208A (ja) 2013-06-13
CN104771364B (zh) 2018-05-25
WO2011112558A2 (en) 2011-09-15
MY156888A (en) 2016-04-15
ZA201207093B (en) 2013-05-29
KR20130048210A (ko) 2013-05-09
IL221833A (en) 2017-01-31
ECSP12012148A (es) 2012-10-30
AR081736A1 (es) 2012-10-17
EA201290892A1 (ru) 2013-03-29
CN103118681B (zh) 2015-02-18
CN103118681A (zh) 2013-05-22
TWI490218B (zh) 2015-07-01
JP5717768B2 (ja) 2015-05-13
US20110312973A1 (en) 2011-12-22
EP2544689B1 (en) 2017-01-11
TW201202239A (en) 2012-01-16
KR101579079B1 (ko) 2015-12-21
UY33265A (es) 2011-10-31
CN104771364A (zh) 2015-07-15
SG183985A1 (en) 2012-10-30
EP2544689A2 (en) 2013-01-16
AU2011224558A1 (en) 2012-09-27
CO6640208A2 (es) 2013-03-22
AU2011224558B2 (en) 2014-02-27
EA021570B1 (ru) 2015-07-30
CA2792601A1 (en) 2011-09-15
UA104517C2 (uk) 2014-02-10
JP5890553B2 (ja) 2016-03-22
GT201200257A (es) 2014-09-26
MX2012010478A (es) 2013-02-01
DOP2012000245A (es) 2013-02-15
CL2012002500A1 (es) 2012-12-07
JP2015145387A (ja) 2015-08-13
NZ602288A (en) 2014-02-28
ES2613608T3 (es) 2017-05-24

Similar Documents

Publication Publication Date Title
PE20130198A1 (es) Composiciones solidas
WO2010084115A3 (en) Antiviral agents
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
PE20150202A1 (es) Compuestos antivirales
CY1118279T1 (el) Φαρμακευτικeς συνθeσεις
CL2007000362A1 (es) Compuestos derivados de octahidropirrolo {3,4-c}pirrol sustituidos,antagonistas de los receptores ccr5 de quimioquinas ccr5;composicion farmaceutica;y su uso en el tratamiento o prevencion de infecciones por virus de la inmunodeficiencia humana (vih-1)o para tratar el sida ao el arc.
PE20110212A1 (es) (1aR, 5S, 8S, 10R, 22aR)-5-TERT-BUTIL-N-{(1R, 2S)-1-{[(CICLOPROPILSULFONIL) AMINO] CARBONIL}-2-VINILCICLOPROPIL}-14-METOXI-3,6-DIOXO-1, 1a, 3, 4, 5, 6, 9, 10, 18, 19, 20, 21, 22, 22a-TETRADECAHIDRO-8H-7, 10-METANOCICLOPROPA[18, 19] [1, 10, 3, 6] DIOXADIAZACICLONONADECINO[11, 12-b] QUINOXALIN-8-CARBOXAMIDA COMO INHIBIDOR DE LA PROTEASA HCV NS3
CL2011002016A1 (es) Compuestos derivados de benzimidazol con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; utiles en el tratamiento de una infeccion por el virus de la hepatitis c (vhc).
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
GT201300077AA (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas (solicitud de patente fraccionaria de la solicitud no. a-2013-00077)
CR20150199A (es) Análogos de 2´-cloro nucleósido para infección por vhc
PE20080070A1 (es) Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c
ECSP10010210A (es) Compuestos nucleósidos antivirales
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
CL2011002878A1 (es) Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih.
PE20121524A1 (es) Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
AR084393A1 (es) Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
EA201390822A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
GEP20247600B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
CO6541645A2 (es) Compuestos de indol y su uso farmaceutico
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
CL2013000727A1 (es) Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c.

Legal Events

Date Code Title Description
FC Refusal
AE Restoration of lapsed or forfeited application
FG Grant, registration